Henrik Möbitz
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Chromatin Remodeling and Cancer, Computational Drug Discovery Methods, Mechanisms of cancer metastasis, Melanoma and MAPK Pathways, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers(2018)228 cited
- → Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors(2011)129 cited
- → Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor(2015)103 cited
- → The ABC of protein kinase conformations(2015)102 cited
- → Type II Inhibitors Targeting CDK2(2015)101 cited
- → Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides(2012)98 cited
- → Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers(2024)98 cited
- → Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach(2016)62 cited
- → A Birch-like Mechanism in Enzymatic Benzoyl-CoA Reduction: A Kinetic Study of Substrate Analogues Combined with an ab Initio Model(2002)60 cited
- → Structural biology contributions to tyrosine kinase drug discovery(2009)51 cited